ABBOTT INDIA
Quarterly Results Analysis [Sep2024]
ABBOTT INDIA Quarterly Results
Standalone | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,633 Cr | ₹1,558 Cr | ₹1,439 Cr | ₹1,437 Cr | ₹1,494 Cr | ₹1,479 Cr | ₹1,343 Cr | ₹1,322 Cr |
Expenses | ₹1,194 Cr | ₹1,167 Cr | ₹1,109 Cr | ₹1,049 Cr | ₹1,113 Cr | ₹1,124 Cr | ₹1,063 Cr | ₹1,010 Cr |
Operating Income | ₹439 Cr | ₹391 Cr | ₹330 Cr | ₹388 Cr | ₹381 Cr | ₹355 Cr | ₹280 Cr | ₹312 Cr |
Other Income | ₹60 Cr | ₹67 Cr | ₹81 Cr | ₹56 Cr | ₹56 Cr | ₹56 Cr | ₹50 Cr | ₹44 Cr |
Interest | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr |
Depreciation | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr |
Profit Before Tax | ₹479 Cr | ₹437 Cr | ₹390 Cr | ₹422 Cr | ₹415 Cr | ₹390 Cr | ₹308 Cr | ₹335 Cr |
Profit After Tax | ₹359 Cr | ₹328 Cr | ₹287 Cr | ₹311 Cr | ₹313 Cr | ₹290 Cr | ₹231 Cr | ₹247 Cr |
EPS | ₹168.76 | ₹154.36 | ₹135.09 | ₹146.34 | ₹147.27 | ₹136.58 | ₹108.90 | ₹116.16 |
Industry Peers & Returns | 1W | 1M | 1Y |
ABBOTT INDIA | 1.2% | 2.7% | 28.9% |
SUN PHARMACEUTICAL INDUSTRIES | 1% | 0.7% | 47.3% |
CIPLA | 0.3% | -1.8% | 19.6% |
DR REDDYS LABORATORIES | 6% | 11.8% | 20.3% |
ZYDUS LIFESCIENCES | -1.5% | -0.1% | 47% |
DIVIS LABORATORIES | -1.1% | -5.8% | 61.7% |
MANKIND PHARMA | 3.7% | 11.4% | 59.4% |
TORRENT PHARMACEUTICALS | 0.6% | 4.1% | 59.5% |
LUPIN | 3.3% | 2.9% | 75.9% |
ABBOTT INDIA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 4.82 % |
Y-o-Y | 9.27 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹1,633 Cr | 4.82 | |
Jun2024 | ₹1,558 Cr | 8.27 | |
Mar2024 | ₹1,439 Cr | 0.10 | |
Dec2023 | ₹1,437 Cr | -3.81 | |
Sep2023 | ₹1,494 Cr | 1.02 | |
Jun2023 | ₹1,479 Cr | 10.12 | |
Mar2023 | ₹1,343 Cr | 1.58 | |
Dec2022 | ₹1,322 Cr | - |
ABBOTT INDIA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 12.26 % |
Y-o-Y | 15.25 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹439 Cr | 12.26 | |
Jun2024 | ₹391 Cr | 18.66 | |
Mar2024 | ₹330 Cr | -15.00 | |
Dec2023 | ₹388 Cr | 1.79 | |
Sep2023 | ₹381 Cr | 7.29 | |
Jun2023 | ₹355 Cr | 26.73 | |
Mar2023 | ₹280 Cr | -10.28 | |
Dec2022 | ₹312 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 7.13 % |
Y-o-Y | 5.49 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 26.89% | 7.13 | |
Jun2024 | 25.1% | 9.56 | |
Mar2024 | 22.91% | -15.09 | |
Dec2023 | 26.98% | 5.85 | |
Sep2023 | 25.49% | 6.21 | |
Jun2023 | 24% | 15.05 | |
Mar2023 | 20.86% | -11.65 | |
Dec2022 | 23.61% | - |
ABBOTT INDIA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 9.33 % |
Y-o-Y | 14.59 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹359 Cr | 9.33 | |
Jun2024 | ₹328 Cr | 14.27 | |
Mar2024 | ₹287 Cr | -7.69 | |
Dec2023 | ₹311 Cr | -0.63 | |
Sep2023 | ₹313 Cr | 7.82 | |
Jun2023 | ₹290 Cr | 25.42 | |
Mar2023 | ₹231 Cr | -6.24 | |
Dec2022 | ₹247 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 4.27 % |
Y-o-Y | 4.87 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 21.96 % | 4.27 | |
Jun2024 | 21.06 % | 5.56 | |
Mar2024 | 19.95 % | -7.81 | |
Dec2023 | 21.64 % | 3.34 | |
Sep2023 | 20.94 % | 6.73 | |
Jun2023 | 19.62 % | 13.87 | |
Mar2023 | 17.23 % | -7.71 | |
Dec2022 | 18.67 % | - |
ABBOTT INDIA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 9.33 % |
Y-o-Y | 14.59 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹168.76 | 9.33 | |
Jun2024 | ₹154.36 | 14.26 | |
Mar2024 | ₹135.09 | -7.69 | |
Dec2023 | ₹146.34 | -0.63 | |
Sep2023 | ₹147.27 | 7.83 | |
Jun2023 | ₹136.58 | 25.42 | |
Mar2023 | ₹108.9 | -6.25 | |
Dec2022 | ₹116.16 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD